Global Primary Hyperoxaluria Drugs Pipeline Market Therapeutics Insights 2017 report provides Primary Hyperoxaluria therapeutics market growth and companies, universities, and institutes product development for Primary Hyperoxaluria. Report also includes global Primary Hyperoxaluria pipeline project overview 2017.
- Agency -.
Primary Hyperoxaluria Pipeline Review H2 2017 provides an overview of the Primary Hyperoxaluria (Genito Urinary System and Sex Hormones) pipeline landscape. Report also provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System and Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Primary Hyperoxaluria Therapeutics Development Companies Profiled in report are Allena Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc, OxThera AB.
- Agency -.
Primary Hyperoxaluria (Genito Urinary System and Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 2 respectively.
Drugs Profiled in report - ALLN-177, ALLN-230, ALN-GO1, DCR-PHXC, Oligonucleotides for Primary Hyperoxaluria, Oxabact.
Access Copy of this report at www.reportsnreports.com/purchase.aspx?name=1153607
Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of Contents
- Number of Products under Development for Primary Hyperoxaluria, H2 2017
- Number of Products under Development by Companies, H2 2017
- Products under Development by Companies, H2 2017
- Number of Products by Stage and Target, H2 2017
- Number of Products by Stage and Mechanism of Action, H2 2017
- Number of Products by Stage and Route of Administration, H2 2017
- Number of Products by Stage and Molecule Type, H2 2017
- Primary Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2017
- Primary Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
- Primary Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2017
- Primary Hyperoxaluria - Pipeline by Intellia Therapeutics Inc, H2 2017
- Primary Hyperoxaluria - Pipeline by OxThera AB, H2 2017
- Primary Hyperoxaluria - Dormant Projects, H2 2017
- Primary Hyperoxaluria - Discontinued Products, H2 2017
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.
For more information: